Key facts
- This page summarizes Patrick Verta's Form 3 filing for InspireMD, Inc. (NSPR).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Oct 2023, 16:15.
Patrick Verta - 02 Oct 2023 Form 3 Insider Report for InspireMD, Inc. (NSPR)
- Reporting relationship
- EVP Clinical/Medical Affairs
- Issuer ticker
- NSPR
- Reported as of
- 02 Oct 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 10 Oct 2023, 16:15:37 UTC
- Next SEC filing
- 25 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick Verta
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Patrick Verta filed Form 3 for InspireMD, Inc. (NSPR) on 10 Oct 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NSPR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 142,740
- Date
- 02 Oct 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NSPR
holding
Derivative
Options to purchase common stock (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Oct 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 46,580
- Exercise price
- $3.30
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares of common stock represent (1) 3,000 shares of common stock purchased by the Reporting Person on the open market and (2) 139,740 shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of October 2, 2024, October 2, 2025 and October 2, 2026, subject to the Reporting Person's continued service.
Footnote F2
The options vest and become exercisable in three equal installments, with 1/3 vesting on each of October 2, 2024, October 2, 2025 and October 2, 2026, subject to the Reporting Person's continued service.